Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma

NCT05290194 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Radiotherapy
PD-1 Inhibitor
Capecitabine
Nasopharyngeal Carcinoma

Interventions

RADIATION: SBRT radiotherapy + Conventionally fractionated radiotherapy
DRUG: PD-1 inhibitor
DRUG: Capecitabine

Sponsor

Fifth Affiliated Hospital, Sun Yat-Sen University